CD73 Inhibitor Compounds for Adenosine-Mediated Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, infections, and neurodegenerative diseases are inadequate, particularly due to the immunosuppressive effects of CD73, which contributes to therapy resistance and immune evasion.
Innovation Solution
Development of compounds that inhibit CD73 activity, including those of Formula (I) and their pharmaceutically acceptable salts, which can be administered alone or in combination with other therapeutic agents to target CD73 and modulate adenosine production, thereby enhancing the effectiveness of cancer treatments and addressing neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for cancer, infections, and neurodegenerative diseases, then existing therapeutic protocols are maintained, but therapy resistance and immune evasion occur due to CD73-mediated adenosine production
Solution Approach 1:
The patent converts the harmful immunosuppressive effect of CD73 into a beneficial therapeutic target. By developing inhibitors that block CD73 activity, the patent transforms the pathway that causes therapy resistance into a target for improving treatment effectiveness. The inhibitors convert adenosine-mediated immunosuppression from a harmful factor into a controlled therapeutic mechanism that enhances immune response against tumors and pathogens.
Solution Approach 2:
The patent introduces CD73 inhibitors as intermediary compounds that mediate between the existing therapeutic agents and the immune system. These inhibitors act as mediators that block the CD73 enzyme's ability to produce adenosine, thereby preventing the immunosuppressive signal transmission that would otherwise interfere with the effectiveness of cancer treatments, antiviral therapies, and neurodegenerative disease management.
2Productivity
If CD73 activity is inhibited to reduce adenosine production, then immune responses are enhanced and tumors are re-sensitized to therapy, but new pharmacological agents must be developed and tested
Solution Approach 1:
The patent creates CD73 inhibitors with universal applicability across multiple disease types including cancer, viral infections, and neurodegenerative diseases. The inhibitors serve multiple functions by simultaneously blocking CD73 activity, reducing adenosine production, and enhancing immune responses in diverse pathological contexts. This multi-functionality allows a single class of compounds to address different diseases through a common mechanism of action.
Solution Approach 2:
The patent employs parameter changes in the chemical structure of CD73 inhibitors to optimize their pharmacological properties. By modifying molecular parameters such as substituent groups, stereochemistry, and structural scaffolds, the patent develops compounds with improved potency, selectivity, and pharmacokinetic profiles. This systematic variation of chemical parameters enables the optimization of inhibitor effectiveness while managing the complexity of drug development.
3Reliability
If combination therapy with CD73 inhibitors is used, then therapeutic benefits are enhanced for cancers and infections, but treatment protocols become more complex
Solution Approach 1:
The patent implements preliminary action by pre-combining CD73 inhibitors with other therapeutic agents in formulated pharmaceutical compositions. This approach allows the inhibitors to be administered together with chemotherapy agents, antivirals, or other therapies in a coordinated manner, ensuring that the immune-enhancing effects of CD73 inhibition are present before and during the administration of other treatments. This preliminary coordination simplifies the overall treatment protocol compared to developing ad-hoc combination regimens.
Data Source
AI summary
Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.